The present invention resides in the discovery that combined use of kuraridin (or any one of its analogs) and epicatechin gallate (ECG) can provide heightened level of antimicrobial activity, especially for the suppression of bacteria of the Staphylococcus aureus and Staphylococcal species. Compositions, kits, and methods for the combination use are disclosed.

The present invention resides in the discovery that combined use of kuraridin (or any one of its analogs) and epicatechin gallate (ECG) can provide heightened level of antimicrobial activity, especially for the suppression of bacteria of the Staphylococcus aureus and Staphylococcal species. Compositions, kits, and methods for the combination use are disclosed.

The invention belongs to the technical field of biomedicament, and more specifically relates to an application of compound amino acids in preparation of a medicament for improving sensitivity of bacteria to antibiotics. Experiments have shown that a combination of compound amino acids and antibiotics can improve the sensitivity of bacteria to antibiotics, promote an entry of antibiotics into bacterial cells, significantly increase an intracellular antibiotic content, and improve a bactericidal effect of antibiotics, thereby reducing a survival rate of bacteria, and treating diseases caused by bacterial infection.

The invention belongs to the technical field of biomedicament, and more specifically relates to an application of compound amino acids in preparation of a medicament for improving sensitivity of bacteria to antibiotics. Experiments have shown that a combination of compound amino acids and antibiotics can improve the sensitivity of bacteria to antibiotics, promote an entry of antibiotics into bacterial cells, significantly increase an intracellular antibiotic content, and improve a bactericidal effect of antibiotics, thereby reducing a survival rate of bacteria, and treating diseases caused by bacterial infection.

The present disclosure provides a piperacillin-containing composition, which further containing a certain proportion of ampicillin and sulbactam. The present disclosure further provides a pharmaceutical formulation thereof and the use thereof. The composition and pharmaceutical formulation of the present disclosure can inhibit the drug-resistant Acinetobacter baumannii, and particularly have therapeutic effects on the infection caused by Acinetobacter baumannii which is resistant to carbapenem or cefoperazone-sulbactam.

The present disclosure provides a piperacillin-containing composition, which further containing a certain proportion of ampicillin and sulbactam. The present disclosure further provides a pharmaceutical formulation thereof and the use thereof. The composition and pharmaceutical formulation of the present disclosure can inhibit the drug-resistant Acinetobacter baumannii, and particularly have therapeutic effects on the infection caused by Acinetobacter baumannii which is resistant to carbapenem or cefoperazone-sulbactam.

The present disclosure provides a piperacillin-containing composition, which further containing a certain proportion of ampicillin and sulbactam. The present disclosure further provides a pharmaceutical formulation thereof and the use thereof. The composition and pharmaceutical formulation of the present disclosure can inhibit the drug-resistant Acinetobacter baumannii, and particularly have therapeutic effects on the infection caused by Acinetobacter baumannii which is resistant to carbapenem or cefoperazone-sulbactam.

The present application relates to method of vaccinating a subject against infection by an enveloped virus. The method includes providing a compound of the Formula (I) as described herein, and contacting the compound of Formula (I) with an isolated enveloped virus, having a membrane, to inactivate the membrane of the isolated enveloped virus. The subject is then treated with the enveloped virus having an inactivated membrane to vaccinate the subject against the enveloped virus. Further disclosed is an ex vivo vaccine composition including the compound of Formula (I) and an enveloped virus.

The present application relates to method of vaccinating a subject against infection by an enveloped virus. The method includes providing a compound of the Formula (I) as described herein, and contacting the compound of Formula (I) with an isolated enveloped virus, having a membrane, to inactivate the membrane of the isolated enveloped virus. The subject is then treated with the enveloped virus having an inactivated membrane to vaccinate the subject against the enveloped virus. Further disclosed is an ex vivo vaccine composition including the compound of Formula (I) and an enveloped virus.

Therapeutic methods comprising the administration of 8-hydroxyquinoline-7-carboxylic acid or a pharmaceutically acceptable salt thereof and an antibacterial agent are disclosed. Also disclosed are combinations and kits comprising 8-hydroxyquinoline-7-carboxylic acid or a pharmaceutically acceptable salt thereof and an antibacterial agent.